 |
Market-Leading XIENCE is Prime Example of Abbott Innovation
Abbott's XIENCE family of drug eluting stents (which includes XIENCE V®, XIENCE PRIME™ and XIENCE nano™) is the worldwide drug eluting stent market leader for the treatment of coronary artery disease.
|
 |
Abbott's Longford, Ireland, Facility Celebrates Delivery of One-Billionth Test
Abbott's Longford, Ireland, facility has been manufacturing medical diagnostic tests for global markets since 2005.
|
 |
Abbott Delivers Industry-Leading Performance for 2011
Abbott delivered its fifth consecutive year of double-digit ongoing earnings per share (EPS) growth with sales increasing more than 10 percent to $38.9 billion in 2011 driven by strong performance across its diverse businesses, particularly in emerging markets.
|
